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Abstract The ten mammalian small heat shock proteins
(sHSPs/HSPBs) show a different expression profile, although
the majority of them are abundant in skeletal and cardiac mus-
cles. HSPBs form hetero-oligomers and homo-oligomers by
interacting together and complexes containing, e.g., HSPB2/
HSPB3 or HSPB1/HSPB5 have been documented in mam-
malian cells and muscles. Moreover, HSPB8 associates with
the Hsc70/Hsp70 co-chaperone BAG3, in mammalian, skele-
tal, and cardiac muscle cells. Interaction of HSPB8 with
BAG3 regulates its stability and function. Weak association
of HSPB5 and HSPB6 with BAG3 has been also reported
upon overexpression in cells, supporting the idea that BAG3
might indirectly modulate the function of several HSPBs.
However, it is yet unknown whether other HSPBs highly
expressed in muscles such as HSPB2 and HSPB3 also bind
to BAG3. Here, we report that in mammalian cells, upon
overexpression, HSPB2 binds to BAG3with an affinity weak-
er than HSPB8. HSPB2 competes with HSPB8 for binding to
BAG3. In contrast, HSPB3 negatively regulates HSPB2 asso-
ciation with BAG3. In human myoblasts that express HSPB2,
HSPB3, HSPB8, and BAG3, the latter interacts selectively
with HSPB8. Combining these data, it supports the interpre-
tation that HSPB8-BAG3 is the preferred interaction.
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Introduction
The family of mammalian small heat shock proteins (HSPs)
comprises ten members that according to the new nomenclature
have been named HSPB1-HSPB10. Although these 10 HSPBs
share a high sequence homology, they can widely differ in term
of expression profile and biochemical properties. Concerning the
expression profile, while some members like, e.g. HSPB1,
HSPB5, and HSPB8 are widely expressed, other members such
as, e.g. HSPB4, HSPB9, and HSPB10 are selectively expressed
in the eye lens (HSPB4) or male germ cells (HSPB9 and
HSPB10). Moreover, HSPB2 and HSPB3 are selectively
expressed in differentiated skeletal and cardiac muscles, where
they form a complex (Sugiyama et al. 2000). Curiously, the
muscles express the largest variety of HSPBs, namely HSPB1,
HSPB2, HSPB3, HSPB5, HSPB6, HSPB7, and HSPB8
(Fontaine, Sun et al. 2005). This suggests that HSPB functions
are important for the development and/or maintenance of mus-
cles. This interpretation is supported by the findings that muta-
tions in several HSPBs have been found associated with neuro-
muscular and muscular diseases, including HSPB1, HSPB3,
HSPB5, and HSPB8 (Vicart, Caron et al. 1998; Evgrafov,
Mersiyanova et al. 2004; Irobi, Van Impe et al. 2004; Kolb,
Snyder et al. 2010; Ghaoui, Palmio et al. 2015). Moreover, dou-
ble knockout in mice of HSPB2 and HSPB5 leads to severe
muscle degeneration with aging, further supporting the notion
that these chaperones are required for muscle health and mainte-
nance (Brady, Garland et al. 2001).
Concerning the biochemical properties, some HSPBs form
large oligomers by interacting with themselves or other mem-
bers of the HSPB family. For example, HSPB1 and HSPB5
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form large homo-oligomers; however, mixed HSPB1 and
HSPB5 assemblies have also been reported both in mamma-
lian cells, tissue, or in vitro (Zantema, Verlaan-De Vries et al.
1992; Liu and Welsh 1999; Sugiyama et al. 2000). By
interacting together, HSPB2 and HSPB3 form hetero-
oligomeric complexes with a specific subunit ratio of 3:1; in
particular, 4-, 8-, 12-, 16- and 24-mer with the fixed 3:1 ratio
have been documented (den Engelsman, Boros et al. 2009).
HSPB2-HSPB3 complex formation has been shown not only
in test tube, but also in cells and muscles (Sugiyama et al.
2000; den Engelsman, Boros et al. 2009). Besides being able
to homo- and hetero-oligomerize, HSPB8 stably interacts with
BAG3, a co-chaperone of Hsc70/Hsp70 (Carra, Seguin et al.
2008). In particular, in mammalian cells and muscle, HSPB8
forms a stable complex with BAG3 with a stoichiometry of
2:1 (Carra, Seguin et al. 2008; Fuchs, Poirier et al. 2010).
Since the discovery of the HSPB8-BAG3 complex, binding
to BAG3 has been documented in mammalian cells also for
HSPB5 (Hishiya, Salman et al. 2011) and HSPB6 (Fuchs,
Poirier et al. 2010); however, their binding affinity to BAG3
is much weaker compared to the one of HSPB8, and compe-
tition for binding to BAG3 between HSPB8 and these HSPBs
occurs (Fuchs, Poirier et al. 2010).
Here, we investigated in mammalian cells whether other
HSPBs can bind to BAG3 with affinities similar to the one
of HSPB8. We focused on the HSPBs that are expressed in
muscles, and we excluded from our study HSPB4, HSPB9,
and HSPB10 (due to their restricted expression profile). We
confirm that HSPB5 weakly binds to BAG3 in mammalian
cells (Hishiya, Salman et al. 2011). Interestingly, we found
that HSPB2, but not HSPB3, can weakly bind to BAG3 upon
overexpression in mammalian cells. HSPB2, and not HSPB2-
HSPB8 hetero-dimers, directly binds to BAG3; moreover,
HSPB2 competes with HSPB8, since increasing the expres-
sion levels of HSPB8 displaces HSPB2 from its association
with BAG3. Similarly, co-expression of HSPB3 with HSPB2
negatively regulates its association with BAG3. The weak and
competitive nature of HSPB2 binding to BAG3 was further
confirmed in human differentiated myoblasts, where HSPB8-
BAG3 is the preferred interaction, and no stable association of
HSPB2 with BAG3 was observed.
Methods
Cell culture and transfection
HEK293T cells (human embryonic kidney-293 cells express-
ing the large T-antigen of SV40/simian virus 40) were grown
in Dulbecco’s modified Eagle’s medium with a high glucose
concentration (Euroclone) supplemented with 10% (v/v) fetal
bovine serum (Sigma-Aldrich). Cells were transfected by cal-
cium phosphate precipitation as described previously (Carra,
Seguin et al. 2008). Human immortalized myoblasts
(LHCNM2 cells) were a kind gift from Prof. E. Pegoraro
(Italy). Cycling LHCNM2 cells were cultured in HAM’s
F12 (EuroClone) supplemented with 2-mM L-glutamine,
100-U/mL penicillin/streptomycin, 20% FBS (Gibco) and
25 ng /mL of rh FGF-b /FGF-2 ( ImmunoTool s ) .
Differentiated LHCNM2 cells were cultured in DMEM sup-
plemented with 2-mM L-glutamine, 100-U/mL penicillin/
streptomycin, 2% horse serum (Gibco), and 30 μg/mL of in-
sulin. siRNA (small interfering RNA) for HSPB8 (target se-
quence: AGAGCAGUUUCAACAACGA) and control se-
quence (siCONTROL non-targeting siRNA) were from
Dharmacon. siRNAs were transfected using Lipofectamine
2000 (Life Technologies) according to the manufacturer’s in-
structions. The cDNAs used in this study are the following:
pci-His-BAG3 and pci-His-dB8-BAG3 (Fuchs et al. 2010);
FRT-TO-V5-HSPB1-HSPB8, FRT-TO-HSPB2 and FRT-TO-
HSPB3 (Vos, Zijlstra et al. 2010). FRT-TO-myc-HSPB3 was
generated by PCR using FRT-TO-HSPB3 as template.
Transfections of the above-mentioned cDNAs were per-
formed using the calcium phosphate method (Carra, Seguin
et al. 2008).
Purification of His-tagged BAG3 with Ni-NTA beads
HEK293T cells were transfected with cDNA encoding for
His-tagged BAG3 (His-BAG3) and either an empty vector
(control) or vectors encoding for V5-tagged HSPBs (Vos,
Zijlstra et al. 2010). Twenty-four-hours post-transfection, cells
were scraped and homogenized in lysis buffer containing 20-
mM Tris/HCl, pH 7.4, 2.5-mM MgCl2, 3% (v/v) glycerol,
0.5%NP40 (Nonidet P40), 150-mMNaCl, 10-mM imidazole,
1-mM DTT and 1× complete protease inhibitor cocktail
(Roche). The cell lysates were centrifuged at 14.000g at
4 °C to pellet the NP40 insoluble proteins. His-BAG3 was
purified from NP40-soluble lysates using Ni-NTA agarose
beads (Qiagen). After 1 h of incubation at 4 °C, the Ni-NTA
beads were washed three times with lysis buffer, followed by
two other washes using a washing buffer enriched in imidazol
(20-mMTris/HCl, pH 7.4, 2.5-mMMgCl2, 3% (v/v) glycerol,
0.5% NP40, 300-mM NaCl, 20-mM imidazol, and 1× com-
plete protease inhibitor cocktail). The proteins bound to the
beads were recovered by boiling in 2% SDS sample buffer.
The input and the bead fractions were then separated by SDS/
PAGE (12.5% gel) and analyzed by Western blotting. BAG3
was used as a loading control.
Co-immunoprecipitation with anti-V5 and anti-myc
antibodies
HEK293T cells were transfected with cDNA encoding for
His-BAG3, V5-tagged HSPBs (Carra, Seguin et al. 2008;
Vos, Zijlstra et al. 2010) or myc-tagged HSPB3. Twenty-
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four hours post-transfection, cells were scraped and homoge-
nized in lysis buffer containing 20-mMTris/HCl, pH 7.4, 1.25-
mMMgCl2, 3.3% (v/v) glycerol, 0.5% NP40, 150-mMNaCl,
1-mM DTT and 1× complete protease inhibitor cocktail). The
cell lysates were centrifuged at 14.000g at 4 °C to pellet the
NP40 insoluble proteins; the NP40 soluble fraction was sub-
jected to co-immunoprecipitation. V5-tagged HSPBs or myc-
tagged HSPB3 were immunoprecipitated using protein A/G
sepharose beads coated with anti-V5 or anti-myc antibodies,
respectively. After 1 h of incubation at 4 °C, the beads were
extensively washed in lysis buffer, and the immunocomplexes
were recovered by boiling in 2% SDS sample buffer. The
input and the bead fractions were separated by SDS/PAGE
(12.5% gel) and analyzed by Western blotting. Unless other-
wise indicated, BAG3 was used as a loading control.
Preparation of samples for western blotting
HEK293T or LHCNM2 cells were lysed in Laemmli sample
buffer containing 2% SDS and homogenized by sonication.
Protein samples were boiled for 3 min at 100 °C, reduced with
β-mercaptoetanol and separated by SDS-PAGE.
Antibodies
The antibodies used in this study are the following: mouse
monoclonal anti-HSPB2 (sc-136,339, Santa Cruz
Bio techno logy) , r abb i t po lyc lona l an t i -HSPB3
(SAB1100972, Sigma-Aldrich), rabbit polyclonal anti-
Desmin (sc-14,026, Santa Cruz Biotechnology), mouse
monoclonal anti-α-tubulin (T6074, Sigma-Aldrich), rabbit
po lyc lona l an t i -Myogen in (sc -576 , San ta Cruz
Biotechnology), mouse monoclonal anti-V5 (R960–25;
Invitrogen), mouse monoclonal anti-myc (9E10; sc-40,
Santa Cruz Biotechnology), and mouse monoclonal anti-
myc (9E10; kindly provided by Prof. R.M. Tanguay). Rabbit
polyclonal anti-HSPB8 and rabbit polyclonal anti-BAG3were
homemade antibodies kindly provided by Prof. J. Landry
(Carra, Seguin et al. 2008).
Mouse and rabbit HRP-conjugated secondary antibodies
for western blot were from GE Healthcare Europe GmbH.
Immunofluorescence microscopy
Cycling and differentiated LHCNM2 cells were grown on
glass coverslip or plastic chamber slides, respectively. Cells
were washed with cold PBS prior to fixation with 3.7% form-
aldehyde in PBS for 9 min at room temperature, followed by
permeabilization with cold acetone for 5 min at −20 °C. Cells
were blocked in PBS containing 3% BSA and 0.1% Triton
X-100. This blocking solution was also used for incubation
with primary and secondary antibodies, which were per-
formed overnight at 4 °C and for 1 h at room temperature,
respectively. Analysis of the cells was done by confocal im-
aging using a Leica SP2 AOBS system (Leica Microsystems)
equipped with a ×63 oil-immersion lens.
Results
Overexpressed HSPB5 weakly binds to BAG3
in HEK293T cells
As previously mentioned, binding of HSPB5, HSPB6, and
HSPB8 to BAG3 has been demonstrated under overexpres-
sion conditions in HEK293 and HEK293T cells (Carra,
Seguin et al. 2008; Fuchs, Poirier et al. 2010; Hishiya,
Salman et al. 2011). To compare the binding affinity to
BAG3 of different HSPBs, we overexpressed in HEK293T
cells HSPB1, HSPB2, HSPB3, HSPB5, HSPB6, HSPB7,
and HSPB8 together with BAG3. We mainly used V5-
tagged versions of these HSPBs in order to compare their
expression levels. V5-tagged HSPBs have been previously
generated, and their anti-aggregation and pro-degradative
properties towards mutant Huntingtin exon 1 (Htt) or a frag-
ment of Ataxin-3 (SCA3) containing an extended
polyglutamine (polyQ) stretch was tested in HEK293 cells
(Vos, Zijlstra et al. 2010).
First, we co-transfected HEK293T cells with His-
BAG3 and V5-tagged HSPB1, HSPB5, HSPB6, HSPB7,
and HSPB8 (Fig. 1a, b). Twenty-four hours post-transfec-
tion, the cell lysates were subjected to Ni-NTA pull-down.
We confirmed that V5-tagged HSPB8 binds to BAG3
(Fig. 1a, b ). Although expressed at similar levels,
HSPB6 (Fig. 1a) and HSPB7 (Fig. 1b) were not pulled-
down by His-BAG3. Instead, a weak binding was ob-
served for V5-tagged HSPB5 (Fig. 1a). In contrast, al-
though expressed at higher levels than HSPB8, V5-
tagged HSPB1 did not interact with His-BAG3 under
these conditions (Fig. 1b). HSPB1, HSPB5, and HSPB6
have been previously shown to weakly interact with
BAG3 (Fuchs, Poirier et al. 2010; Hishiya, Salman et al.
2011). We were able under these conditions to see some
association of HSPB5 to BAG3, while we had no signal
for HSPB1 and HSPB6. Interestingly, in vitro studies con-
firmed by size-exclusion chromatography and chemical
crosslinking that HSPB6 weakly interacts with BAG3;
however, the complex resulting from this interaction is
much less stable than the HSPB8-BAG3 complex
(Shemetov and Gusev 2011). Considering the weak and
unstable nature of HSPB6 binding to BAG3, our results
suggest that the expression levels of HSPB6 reached in
our experiment were not sufficient to yield stable and
detectable interaction with BAG3. Similarly, HSPB1
binding to BAG3 was detected in cells using mass spec-
trometry followed by quantitative high-throughput
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LUMIER assays (Taipale, Tucker et al. 2014) or in vitro,
using recombinant proteins (Rauch, Tse et al. 2016).
Under these conditions, the affinity of HSPB1 for BAG3
was much weaker compared to the one of HSPB8 (Rauch,
Tse et al. 2016). Collectively, these results support that, in
HEK293T cells, HSPB8 has a greater binding affinity to
BAG3 compared to HSPB5 (Fig. 1a) and, especially,
HSPB6 and HSPB1.
Overexpressed HSPB2, but not HSPB3, weakly binds
to BAG3
We next asked whether HSPB2 and HSPB3, which are
expressed in differentiated skeletal and cardiac muscle cells
(Sugiyama et al. 2000), can bind to BAG3. To test if HSPB2
binds to BAG3, we transfected HEK293T cells with His-
BAG3 alone, used as control, or with V5-tagged HSPB2,
and 24-h post-transfection, we performed an immunoprecipi-
tation using a V5 specific antibody. Considering that HSPB2
and HSPB3 form a stoichiometric complex (den Engelsman,
Boros et al. 2009), we also co-transfected V5-HSPB2 and
myc-HSPB3 together with BAG3 to test whether HSPB2
and HSPB3 in complex might interact with BAG3. Fig. 2a
shows that HSPB2 interacts with BAG3. Interestingly, when
HSPB2 and HSPB3 were co-expressed with BAG3, HSPB3
co-immunoprecipitated with HSPB2, is abrogating the
HSPB2-BAG3 binding (Fig. 2a). We also tested whether
HSPB3 alone might associate with BAG3. We found that
myc-tagged HSPB3 either expressed alone or with HSPB2
did not interact with BAG3 (Fig. 2b). Combining these exper-
iments demonstrates that HSPB3 competes with BAG3 and
abrogates its weak association with HSPB2 (Fig. 2a, b).
We next compared the binding affinity to His-BAG3 of
V5-tagged HSPB2 and HSPB8. We overexpressed in
HEK293T cells His-BAG3 with V5-tagged HSPB1, HSPB2,
or HSPB8. Twenty-four hours post-transfection, the cells were
subjected to immunoprecipitation using the V5 antibody. The
expression levels of these three HSPBs were similar. We con-
firmed that V5-tagged HSPB2 binds to BAG3, although with
a weaker affinity compared to HSPB8 (Fig. 2c). No interac-
tion was detected between HSPB1 and BAG3 under these
conditions (Fig. 2c).
Overexpressed HSPB2 competes with HSPB8 for binding
to BAG3
In contrast to HSPB3 (Fontaine, Sun et al. 2005), HSPB2 has
been shown to interact with HSPB8 (Sun, Fontaine et al.
2004). We verified that the HSPB8 protein is endogenously
expressed in HEK293T cells at detectable levels (Fig. 3a);
instead, HSPB2 and HSPB3 were detected by western blot
only upon transient transfection, further confirming their high-
ly restricted expression profile (Fig. 3a). We then asked
whether the association of overexpressed HSPB2 with
BAG3 was direct or could be mediated by the formation of
HSPB2-HSPB8 heterodimers (due to interaction of
overexpressed HSPB2 with endogenous HSPB8). To address
this question, we overexpressed His-BAG3 with V5-tagged
HSPB2 in control HEK293T cells expressing endogenous
HSPB8 or in HSPB8-depleted HEK293T cells (which were
previously transfected with a specific RNAi targeting
HSPB8). In parallel, we co-expressed in control HEK293T,
Fig. 1 Overexpressed HSPB5 weakly binds to BAG3. a HEK293Tcells
were transfected with cDNAs encoding for V5-tagged HSPB5–8 and
His-tagged BAG3. Twenty-four hours post-transfection, the NP-40 solu-
ble fractions were subjected to Ni-NTA purification. b HEK293T cells
were transfected with cDNAs encoding for V5-tagged HSPB1, HSPB7,
HSPB8, and His-tagged BAG3. Twenty-four hours post-transfection, the
NP-40 soluble fractions were subjected to Ni-NTA purification. Beads
and input fractions from A and B were processed for western blotting
using anti-V5 and anti-BAG3 specific antibodies. BAG3 protein levels in
the input fraction were used as internal loading control
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His-BAG3 with V5-tagged HSPB2 and untagged HSPB8.
Seventy-two hours after the transfection of the HSPB8
RNAi (or a nontargeting sequence used as control) and 24 h
after the overexpression of His-BAG3, V5-HSPB2, and/or
HSPB8, we performed an immunoprecipitation using the V5
antibody. V5-tagged HSPB2 co-immunoprecipitated equal
amounts of BAG3 in both control, and HSPB8-depleted
HEK293T cells, suggesting that HSPB2 directly binds to
BAG3, and that the interaction is not mediated by the forma-
tion of HSPB2-HSPB8 heterodimers (Fig. 3b). Moreover,
HSPB2 binding to BAG3 was abrogated when HSPB8 was
overexpressed. This result opens the possibility that (1)
HSPB2 and HSPB8 compete for binding to BAG3, with
HSPB8 showing a stronger binding affinity to BAG3 than
HSPB2 or (2) overexpressed HSPB8 could bind to HSPB2,
thereby impeding on its association with BAG3, similarly to
Fig. 2 Overexpressed HSPB2,
but not HSPB3, binds to BAG3
with an affinity lower than
HSPB8. a, bHEK293Tcells were
transfected with cDNAs encoding
for V5-tagged HSPB2, myc-
tagged HSPB3 and His-tagged
BAG3, alone or combined.
Twenty-four hours post-t
ransfection, cell lysates were
subjected to co-
immunoprecipitation using an
anti-V5 antibody (a) and or anti-
myc antibody (b). Beads and
input fractions were processed for
western blotting using anti-myc,
anti-V5, and anti-BAG3 specific
antibodies. BAG3 protein levels
in the input fraction were used as
internal loading control. A:
asterisk corresponds to IgG non-
specific signal; arrowhead
indicates myc-HSPB3. c
HEK293T cells were transfected
with cDNAs encoding for V5-
tagged HSPB1, HSPB2, HSPB8,
and his-tagged BAG3. Twenty-
four hours post-transfection, cells
were processed as described in A.
Quantitation of the total amount
of BAG3 co-immunoprecipitated
by HSPB8 and HSPB2
(**p = 0.00191; average
values ± s.e.m. of n = 3
independent experiments)
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HSPB3 (Fig. 2a). To test this hypothesis, we compared the
binding affinity of HSPB8 or BAG3 to HSPB2. HEK293T
cells were transfected with his-HSPB2 and myc-tagged
HSPB8 or BAG3, and 24-h post-transfection, cell lysates were
Fig. 3 HSPB8 strongly competes with HSPB2 for binding to BAG3. a
HEK293Tcells express endogenous HSPB8, but not HSPB2 nor HSPB3.
HEK293T cells were transfected for 24 h with cDNAs encoding for
HSPB2 or myc-tagged HSPB3. Protein extracts were subjected to
western blotting using antibodies specific for HSPB2, HSPB3, and
HSPB8. α-Tubulin was used as internal loading control. b HEK293T
cells were left untreated or transfected with a specific siRNA against
HSPB8. 48 h later, cells were transfected with cDNAs encoding for his-
tagged BAG3, V5-HSPB2, and/or HSPB8. Twenty-four hours post-
transfection, the cells were subjected to co-immunoprecipitation using
an anti-V5 antibody. Beads and input fractions were processed for
western blotting using anti-V5, anti-HSPB8, and anti-BAG3 specific
antibodies. γ-Tubulin was used as internal loading control. c HEK293T
cells were transfected with cDNAs encoding for his-HSPB2 and myc-
HSPB8 or myc-BAG3. Twenty-four hours post-transfection, cells were
subjected to Ni-NTA purification. Beads and input fractions were
processed for western blotting using anti-HSPB2 and anti-myc specific
antibodies. d HEK293T cells were transfected with cDNAs encoding for
V5-tagged HSPB1, HSPB2, and His-tagged BAG3, or the deletion
mutant dB8-BAG3 (unable to bind to HSPB8). Cells expressing his-
tagged BAG3 or dB8-BAG3 alone were used as negative controls (right
panel). Twenty-four hours post-transfection, the NP-40 soluble
fractions were subjected to co-immunoprecipitation using an anti-V5 an-
tibody. Beads and input fractions were processed for western blotting
using anti-V5 and anti-BAG3 specific antibodies. BAG3 protein levels
were used as internal loading control. Arrowheads indicates IgG non-
specific signal
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subjected to Ni-NTA pull-down. Fig. 3c shows, using an anti-
myc antibody, that myc-BAG3 binds to his-HSPB2 with a
higher affinity compared to myc-HSPB8. This result strongly
supports our interpretation that, overexpressed HSPB8 com-
petes with HSPB2 for binding to BAG3.
Based on these results, one would expect that HSPB2 and
HSPB8 bind to the same binding region to BAG3. We previ-
ously identified two stretches of amino acids containing two
conserved IPV (Ile-Pro-Val) motifs in BAG3 that mediate its
binding to HSPB8 (Fuchs, Poirier et al. 2010). Deletion of
these specific sequences (amino-acid residues 87–101 and
200–213; dB8-BAG3) abrogates the association between
HSPB8 and BAG3 (Fuchs, Poirier et al. 2010). To test wheth-
er HSPB2 binds to the same residues as HSPB8, we co-
transfected V5-tagged HSPB2 with either His-BAG3 or its
deletion mutant unable to bind to HSPB8 (His-dB8-BAG3),
and 24-h post-transfection, we performed an immunoprecipi-
tation using the V5 antibody. We also co-transfected V5-
tagged HSPB1 with His-BAG3, which, according to our find-
ings, should not stably and detectably interact in HEK293T
cells. HSPB2, but not HSPB1, weakly co-immunoprecipitated
BAG3. Deletion of the amino-acid residues 87–101 and 200–
213 of BAG3 abrogated its association with HSPB2 (Fig. 3d).
Combining these results demonstrates that HSPB2 can inter-
act with BAG3 with a weaker affinity than HSPB8 and that
HSPB2 and HSPB8 compete for binding to the same region.
HSPB8-BAG3 is the preferred interaction also
in differentiated human myoblasts that express HSPB2
and HSPB3
Besides skeletal and cardiac muscle cells, HSPB2 is also
expressed in glioma and breast cancer cells, where it exerts
anti-apoptotic functions (Oshita, Chen et al. 2010). Instead,
HSPB3 is expressed in muscles and in several fetal tissues,
where it has been suggested to participate to embryonic stem
cell differentiation, although experimental evidence
supporting such a function is still lacking (Lam, Wing Tsui
et al. 1996; Pennings, van Dartel et al. 2011). First, here we
verified whether human immortalized myoblasts that are
grown under cycling conditions express endogenous HSPB2
and HSPB3 proteins. In line with previous reports using
mouse immortalized cycling muscle cells (C2C12 cells)
(Sugiyama, Suzuki et al. 2000), no HSPB2 and HSPB3 were
detected in cycling LHCNM2 cells by western blotting
(Fig. 4a). Instead, both HSPB2 and HSPB3 proteins were
induced in LHCNM2 cells differentiated for 5 days (Fig. 4a;
similarly to what previously found in C2C12 cells or muscle
tissue extracts) (Sugiyama et al. 2000). Desmin and
myogenin, which are induced during muscle differentiation,
were used as positive controls to monitor LHCNM2 cell dif-
ferentiation (Fig. 4a). We next performed immunofluores-
cence studies, in human cycling and differentiated myoblasts
to analyze the expression and distribution of endogenous
HSPB2, HSPB3, HSPB8, and BAG3. We confirmed that
HSPB2 and HSPB3 are absent in cycling LHCNM2 cells,
while, upon differentiation, they are distributed throughout
the cells (Fig. 4b, compare cycling and differentiated
LHCNM2 cells). In contrast, HSPB8 and BAG3 are expressed
in both cycling and differentiated LHCNM2 cells, where they
are mainly distributed in the cytosol (Fig. 4b).
Next, we asked whether endogenous HSPB2 can interact
with endogenous BAG3 in differentiated LHCNM2 cells.
LHCNM2 cells were grown in differentiating medium for
7 days, and the cell extracts were subjected to immunoprecip-
itation using the BAG3 antibody. We found that BAG3 co-
immunoprecipitated HSPB8, but not HSPB2 in differentiated
human myoblasts (Fig. 4c). This result is in line with our data
obtained under overexpression conditions showing that
HSPB8 has a higher binding affinity for BAG3 than
HSPB2. Based on these findings, we conclude that also in
human differentiated myoblasts HSPB8-BAG3 is the pre-
ferred interaction.
Discussion
In the present study, we compared the binding affinity to
BAG3 of several HSPB members upon overexpression in
HEK293T cells. Since BAG3 is highly expressed in cardiac
and skeletal muscle cells and its mutations leads to cardiomy-
opathy and muscular dystrophy (Selcen, Muntoni et al. 2009;
Arimura, Ishikawa et al. 2011; Norton, Li et al. 2011; Villard,
Perret et al. 2011; Chami, Tadros et al. 2014; Franaszczyk,
Bilinska et al. 2014; Toro, Perez-Serra et al. 2016), we select-
ed for our study the HSPB proteins that are expressed in skel-
etal and/or cardiac muscle cells, namely HSPB1, HSPB2,
HSPB3, HSPB6, HSPB7, and HSPB8 (Fontaine, Sun et al.
2005). We mainly used V5-tagged forms of these HSPBs in
order to directly compare their expression levels and their
binding affinities to BAG3, using an antibody specific for
the V5 tag. In agreement with published data (Carra, Seguin
et al. 2008; Hishiya, Salman et al. 2011), we confirmed that
HSPB8 binds to BAG3, while HSPB5 only weakly interacted
with it. We found that upon overexpression in HEK293Tcells,
also HSPB2, but not HSPB3, showed weak interaction with
BAG3, compared to HSPB8. Interestingly, such interaction
was regulated by both HSPB8 and HSPB3. In particular,
HSPB8 directly competed with HSPB2 for binding to the
same IPV domains on BAG3, showing a higher affinity and
displacing HSPB2 from such interaction. Instead, HSPB3
interacted with HSPB2, displacing HSPB2 from its weak as-
sociation with BAG3.
Under our experimental conditions, we were unable to detect
interaction between HSPB1, HSPB3, HSPB6, or HSPB7, and
BAG3; however, binding of HSPB1 to BAG3 was documented,
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in human cells, by mass spectrometry and quantitative high-
throughput LUMIER assays (Taipale, Tucker et al. 2014).
Moreover, weak binding of HSPB6 to BAG3 was previously
described both in cells and in vitro, using recombinant proteins
(Fuchs, Poirier et al. 2010; Shemetov and Gusev 2011). This
apparent discrepancy suggests that HSPB1 and HSPB6 would
bind to BAG3 with an affinity that is weaker than the ones of
HSPB5 and HSPB2, at least in HEK293Tcells using V5-tagged
proteins. In particular, binding of HSPB1 or HSPB6 to BAG3
could be below detection level using conventional western blot-
ting, rather than more sensitive techniques like mass spectrome-
try and quantitative high-throughput LUMIER assays (Taipale,
Tucker et al. 2014). Combined with the published data, our re-
sults in HEK293T cells suggest the following hierarchy of
Fig. 4 HSPB8-BAG3 is the preferred complex also in differentiated
human myoblasts. a Human myoblasts (LHCNM2 cells) were grown
under cycling conditions (0 days diff.) or let to differentiate for 5 days
(5 days diff.), prior to extraction of total proteins. Expression levels of
endogenous HSPB2, HSPB3, desmin, and myogenin (used as
differentiation markers) were evaluated by western blotting. α-Tubulin
was used as internal loading control. b Fluorescent microscopy on cycling
and differentiated LHCNM2 cells showing expression and subcellular
distribution of endogenous HSPB2, HSPB3, HSPB8, and BAG3, using
specific antibodies. DAPI was used to stain nucleic acid. Note that
HSPB2 and HSPB3 are detected only in differentiated LHCNM2 cells,
in line with the results shown in panel A. c LHCNM2 cells were
differentiated for 7 days and were then subjected to co-
immunoprecipitation using anti-BAG3 specific antibody. Beads coated
with normal rabbit serum (NRS) were used as negative control. Beads and
input fractions were processed for western blotting using anti-BAG3,
anti-HSPB2, or anti-HSPB8 antibodies. Arrowheads indicates IgG non-
specific signal
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affinities for BAG3: HSPB8 > > HSPB2, HSPB5 and HSPB6,
which all show weaker association (data presented here and pre-
vious reports; (Fuchs, Poirier et al. 2010; Shemetov and Gusev
2011)). This interpretation is in line with recent findings from
Rauch et al., who, using recombinant proteins, also found that
HSPB8 binds to BAG3 with an affinity that is much higher
compared to the ones of HSPB6 and, especially, HSPB1
(Rauch, Tse et al. 2016). However, our results also support that,
based only on co-immunoprecipitation assays performed in
mammalian cells under overexpression conditions, it is not pos-
sible to conclude whether one specific HSPB can or cannot bind
to BAG3, and caution must be taken when interpreting these
data. To firmly establish if a given HSPB displays some binding
capacity to BAG3, studies in vitro with pure recombinant pro-
teins are required (similarly to what has been done with HSPB6
and, recently with HSPB1; (Shemetov and Gusev 2011; Rauch,
Tse et al. 2016)). Thus, although by co-immunoprecipitation in
HEK293T cells, we had no evidence of binding of HSPB3 and
HSPB7, one cannot conclude that such interaction is not occur-
ring; in other words, these data do not exclude the possibility that
using pure recombinant proteins also HSPB3 and HSPB7 could
weakly interact with BAG3. However, although we cannot ex-
clude that some transient binding of several HSPBs to BAG3
might occur, our data strongly demonstrate that HSPB8 has a
high binding affinity for BAG3, and that HSPB8-BAG3 is the
preferred interaction, both in cells and in vitro (Shemetov and
Gusev 2011; Rauch, Tse et al. 2016). This conclusion is further
supported by our experimental findings in human myoblasts
(LHCNM2 cells). In fact, we found that in differentiated
LHCNM2 cells that express HSPB2, HSPB3, HSPB8, and
BAG3, on ly HSPB8, and no t HSPB2, was co-
immunoprecipitated by BAG3. Similarly, when investigating en-
dogenous proteins, the HSPB8-BAG3, but not the HSPB6-
BAG3 complex, was documented in muscle extracts (Fuchs,
Poirier et al. 2010). Taken together, these data demonstrate that
independent on the system used, being it an in vitro system with
pure recombinant proteins, non-muscular cells (Carra, Seguin
et al. 2008) and muscular cells (Fig. 4 and (Fuchs, Poirier et al.
2010)) expressing endogenous or transiently transfected proteins,
the HSPB8-BAG3 complex is the preferred one, and the other
HSPBs need to compete with endogenous HSPB8 for weak and
transient binding to BAG3.
Finally, our results open the possibility that under
specific conditions where HSPB8 levels would be de-
creased or in presence of HSPB8 mutants that have
decreased binding affinity for BAG3, such as for
K141E and K141N-HSPB8 associated with motor neu-
ropathy (Carra et al. 2010; Shemetov and Gusev 2011),
other HSPBs might compete with HSPB8 for interaction
with BAG3, and both HSPB8-BAG3 and, e.g., HSPB2-
BAG3, HSPB5-BAG3, or HSPB6-BAG3 complexes
might transiently co-exist, with potential consequences
on their functions.
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